MedTrace Logo

Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease Patients

NCT03113812 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-04-14

No results posted yet for this study

Summary

This first time study in humans was designed to assess tolerability and safety of repeated subcutaneous injections of ABvac40, an active immunization against the C-terminal end of Abeta1-40.

Conditions

Interventions

DRUG

ABvac40

DRUG

Placebo

Sponsors & Collaborators

  • Araclon Biotech S.L.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-01
Primary Completion
2015-07-30
Completion
2015-07-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03113812 on ClinicalTrials.gov